(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 May 2014 (08.05.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/071122 A1

(51) **International Patent Classification**:
A61K 9/20 (2006.01) *A61K 31/443* (2006.01)
A61K 45/06 (2006.01) *A61K 31/47* (2006.01)

(21) **International Application Number**:
PCT/US2013/067952

(22) **International Filing Date**:
1 November 2013 (01.11.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/721,622	2 November 2012 (02.11.2012)	US
61/728,328	20 November 2012 (20.11.2012)	US
61/770,668	28 February 2013 (28.02.2013)	US
61/824,005	16 May 2013 (16.05.2013)	US
61/840,668	28 June 2013 (28.06.2013)	US

(71) **Applicant**: **VERTEX PHARMACEUTICALS INCORPORATED** [—/US]; 130 Waverly Street, Cambridge, MA 02139 (US).

(72) **Inventors**: **VERWIJS, Marinus, Jacobus**; 4 Carter Drive, Framingham, MA 01701 (US). **KARKARE, Radhika**; 31 Harvard Avenue #44, Medford, MA 02155 (US). **MOORE, Michael, Douglas**; 22 Prospect Street, Unit 1, Charlestown, MA 02129 (US).

(74) **Agent**: **DIVERDI, Michael, J.**; Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2014/071122 A1

(54) **Title**: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES

(57) **Abstract**: Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5- yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4- oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.